{"DataElement":{"publicId":"14776915","version":"1","preferredName":"Overall Lesion Response RECIP 1.0 Type","preferredDefinition":"Text term to represent the overall disease response in the prostate-specific membrane antigen (PSMA)-positive total tumor volume and the occurrence of new lesions using the RECIP criteria.","longName":"OVR_RECIP_TYPE","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"2188872","version":"1","preferredName":"Overall Lesion Response","preferredDefinition":"Information relating to the overall lesion response.","longName":"OVERALL_LES_RESP","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2206600","version":"1","preferredName":"Overall Lesion","preferredDefinition":"Including everything.:(LEE-zhun) An area of abnormal tissue change.","longName":"C25605:C3824","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lesion","conceptCode":"C3824","definition":"A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FBC1-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRECIST: Immune-related Response Evaluation Criteria in Solid Tumours (RECIST)-2013","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E49C180D-8D57-0916-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-10-05","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":"8/7/18 jk added irRECIST CSI.  8/30/17 tt transferred context, added registration status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14776914","version":"1","preferredName":"Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT 1.0 Type","preferredDefinition":"A quantitative assessment that combines changes in the prostate-specific membrane antigen (PSMA)-positive total tumor volume (TTV) and the occurrence of new lesions. It was developed in 2022 to evaluate treatment response using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (Gafita A, Rauscher I, Weber M, et  al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 2022;63(11):1651–1658)._Something distinguishable as an identifiable class based on common qualities.","longName":"RECIP_TYPE","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"RECIP-CR","valueDescription":null,"ValueMeaning":{"publicId":"14776916","version":"1","preferredName":"RECIP 1.0 Complete Response","longName":"14776916v1.00","preferredDefinition":"Absence of any prostate-specific membrane antigen (PSMA) uptake on iPET (interim PET/CT) evaluated after two cycles of treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIP 1.0 Complete Response","conceptCode":"C204132","definition":"Absence of any prostate-specific membrane antigen (PSMA) uptake on iPET (interim PET/CT) evaluated after two cycles of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211E881-E3EC-369C-E063-731AD00A2979","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1211E881-E3F0-369C-E063-731AD00A2979","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","deletedIndicator":"No"},{"value":"RECIP-PR","valueDescription":null,"ValueMeaning":{"publicId":"14776917","version":"1","preferredName":"RECIP 1.0 Partial Response","longName":"14776917v1.00","preferredDefinition":"Greater than or equal to a 30% decrease in prostate-specific membrane antigen (PSMA) volume without the appearance of new lesion(s). A new lesion is defined as any new focal uptake of PSMA ligand that is higher than the surrounding background, or where the tumor maximum standardized uptake value (SUVmax) is greater than blood pool SUVmax or that was not present on baseline scan (tumor SUVmax less than blood pool SUVmax), with tumor uptake not attributable to physiologic uptake or pitfalls, or any new malignant lesion detected on follow-up CT images independent of PSMA ligand uptake.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIP 1.0 Partial Response","conceptCode":"C204133","definition":"Greater than or equal to a 30% decrease in prostate-specific membrane antigen (PSMA) volume without the appearance of new lesion(s). A new lesion is defined as any new focal uptake of PSMA ligand that is higher than the surrounding background, or where the tumor maximum standardized uptake value (SUVmax) is greater than blood pool SUVmax or that was not present on baseline scan (tumor SUVmax less than blood pool SUVmax), with tumor uptake not attributable to physiologic uptake or pitfalls, or any new malignant lesion detected on follow-up CT images independent of PSMA ligand uptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211E881-E3ED-369C-E063-731AD00A2979","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1211E881-E3F1-369C-E063-731AD00A2979","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","deletedIndicator":"No"},{"value":"RECIP-PD","valueDescription":null,"ValueMeaning":{"publicId":"14776918","version":"1","preferredName":"RECIP 1.0 Progressive Disease","longName":"14776918v1.00","preferredDefinition":"Greater than or equal to a 20% increase in prostate-specific membrane antigen (PSMA) volume with the appearance of new lesions. A new lesion is defined as any new focal uptake of PSMA ligand that is higher than the surrounding background, or where the tumor maximum standardized uptake value (SUVmax) is greater than blood pool SUVmax or that was not present on baseline scan (tumor SUVmax less than blood pool SUVmax), with tumor uptake not attributable to physiologic uptake or pitfalls, or any new malignant lesion detected on follow-up CT images independent of PSMA ligand uptake.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIP 1.0 Progressive Disease","conceptCode":"C204134","definition":"Greater than or equal to a 20% increase in prostate-specific membrane antigen (PSMA) volume with the appearance of new lesions. A new lesion is defined as any new focal uptake of PSMA ligand that is higher than the surrounding background, or where the tumor maximum standardized uptake value (SUVmax) is greater than blood pool SUVmax or that was not present on baseline scan (tumor SUVmax less than blood pool SUVmax), with tumor uptake not attributable to physiologic uptake or pitfalls, or any new malignant lesion detected on follow-up CT images independent of PSMA ligand uptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211E881-E3EE-369C-E063-731AD00A2979","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1211E881-E3F2-369C-E063-731AD00A2979","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","deletedIndicator":"No"},{"value":"RECIP-SD","valueDescription":null,"ValueMeaning":{"publicId":"14776919","version":"1","preferredName":"RECIP 1.0 Stable Disease","longName":"14776919v1.00","preferredDefinition":"Less than 30% decrease in prostate-specific membrane antigen (PSMA) volume with or without the appearance of new lesions, or greater than or equal to a 30% decrease in PSMA volume with the appearance of new lesion(s), or less than a 20% increase in PSMA volume with or without the appearance of new lesions, or greater than or equal to a 20% increase in PSMA volume without the appearance of new lesions. A new lesion is defined as any new focal uptake of PSMA ligand that is higher than the surrounding background, or where the tumor maximum standardized uptake value (SUVmax) is greater than blood pool SUVmax or that was not present on baseline scan (tumor SUVmax less than blood pool SUVmax), with tumor uptake not attributable to physiologic uptake or pitfalls, or any new malignant lesion detected on follow-up CT images independent of PSMA ligand uptake.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RECIP 1.0 Stable Disease","conceptCode":"C204135","definition":"Less than 30% decrease in prostate-specific membrane antigen (PSMA) volume with or without the appearance of new lesions, or greater than or equal to a 30% decrease in PSMA volume with the appearance of new lesion(s), or less than a 20% increase in PSMA volume with or without the appearance of new lesions, or greater than or equal to a 20% increase in PSMA volume without the appearance of new lesions. A new lesion is defined as any new focal uptake of PSMA ligand that is higher than the surrounding background, or where the tumor maximum standardized uptake value (SUVmax) is greater than blood pool SUVmax or that was not present on baseline scan (tumor SUVmax less than blood pool SUVmax), with tumor uptake not attributable to physiologic uptake or pitfalls, or any new malignant lesion detected on follow-up CT images independent of PSMA ligand uptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211E881-E3EF-369C-E063-731AD00A2979","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1211E881-E3F3-369C-E063-731AD00A2979","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"14776913","version":"1","preferredName":"Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT 1.0 Type","preferredDefinition":"A quantitative assessment that combines changes in the prostate-specific membrane antigen (PSMA)-positive total tumor volume (TTV) and the occurrence of new lesions. It was developed in 2022 to evaluate treatment response using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (Gafita A, Rauscher I, Weber M, et  al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 2022;63(11):1651–1658)._Something distinguishable as an identifiable class based on common qualities.","longName":"14776913v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA) PET/CT 1.0","conceptCode":"C204131","definition":"A quantitative assessment that combines changes in the prostate-specific membrane antigen (PSMA)-positive total tumor volume (TTV) and the occurrence of new lesions. It was developed in 2022 to evaluate treatment response using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (Gafita A, Rauscher I, Weber M, et  al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 2022;63(11):1651–1658).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211AFFF-2C58-2915-E063-731AD00AD083","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211AFFF-2C59-2915-E063-731AD00AD083","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"},{"publicId":"3308730","version":"1","longName":"MediData Rave Use","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Overall Response","url":null,"context":"CCR"}],"origin":"RECIP: Gafita, A., et al., Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0):an international multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2022. 49(Suppl 1): p. S269-S269.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1211B94C-9DED-2AB3-E063-731AD00AE03E","latestVersionIndicator":"Yes","beginDate":"2024-02-23","endDate":null,"createdBy":"GDEEN","dateCreated":"2024-02-23","modifiedBy":"GDEEN","dateModified":"2024-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}